The $3.95 Million Question: What Fayuvi's Approval Means for Sanfilippo Syndrome and the Price of Miracles

On September 17, 2026, Ultragenyx Pharmaceutical announced that the FDA had granted standard full approval to Fayuvi (rebisufligene etisparvovec-hopf), a single-dose intravenous gene therapy for pediatric patients with Sanfilippo syndrome Type A, also known as mucopolysaccharidosis type IIIA. It is the first treatment ever approved for this disease. Within hours, Ultragenyx set the U.S. list price at $3.95 million, making Fayuvi one of the most expensive drugs in the world.

Both facts deserve to be held together, because they tell a story that is simultaneously about scientific triumph and about the unresolved tension at the center of rare disease medicine: what does society owe to children with diseases so rare that the economics of developing treatments for them are genuinely brutal, and who decides what that obligation is worth?

What Sanfilippo Syndrome Type A Actually Does

Sanfilippo syndrome Type A is caused by a deficiency of the sulfamidase enzyme, encoded by the SGSH gene. Without it, heparan sulfate accumulates in cells throughout the body, with the most devastating consequences in the brain. Children with the disease typically develop normally for the first year or two of life, then begin a relentless regression. Language disappears. Motor function deteriorates. Behavior becomes difficult to manage. The disease progresses through a predictable and heartbreaking sequence until death, which arrives at a median age of 15 years. There are no approved disease-modifying treatments. There have never been any. Until now.

The disease affects an estimated 3,000 to 5,000 patients in commercially accessible geographies globally. That number is not a rounding error. It is the entire patient population. The rarity of the condition is precisely what makes it so difficult to develop treatments for, and precisely what makes the approval of Fayuvi so significant for the families who have been waiting for it.

What the Data Show

Fayuvi uses an AAV9 viral vector to deliver a functional copy of the SGSH gene intravenously, allowing cells to produce the missing enzyme. The approval is supported by data from the pivotal Transpher A trial and long-term follow-up studies, with clinical data now extending to nearly eight years of follow-up. The primary efficacy measure compared Fayuvi-treated patients to an external natural history cohort of untreated patients with the same disease. Treated patients demonstrated a 23.5 point higher mean cognitive score over natural history during the period of study, a difference that reached statistical significance at p less than 0.0001. Biochemical evidence of efficacy was demonstrated by sustained reductions in cerebrospinal fluid heparan sulfate levels across all age groups throughout the study.

The safety profile includes hepatotoxicity as a significant concern, with elevated liver enzymes observed in the majority of patients, managed through corticosteroid prophylaxis and monitoring. Thrombocytopenia and the theoretical risk of thrombotic microangiopathy, a known concern with AAV gene therapies, are also flagged in the prescribing information. These are not trivial considerations, but they are manageable ones, and the benefit-risk calculation for a disease with no alternatives and a median life expectancy of 15 years is not a close call.

The Road That Led Here

The approval did not come easily. The therapy was originally developed at Nationwide Children's Hospital and Ohio State University, licensed to Abeona Therapeutics, and then out-licensed to Ultragenyx when Abeona faced funding constraints despite positive clinical data. The FDA issued a complete response letter at an earlier review stage, citing manufacturing concerns. Ultragenyx resubmitted, the FDA set a new PDUFA date of September 19, 2026, and then approved the drug two days ahead of schedule on September 17. The Cure Sanfilippo Foundation and the National MPS Society, patient advocacy organizations that spent years fundraising and lobbying to keep the program alive, described the approval as a milestone the community spent decades fighting to achieve.

That history matters because it illustrates something important about how ultra-rare disease therapies actually reach patients. They do not follow a clean commercial logic. They survive on a combination of scientific conviction, patient advocacy, regulatory flexibility, and the willingness of companies to absorb development costs that no rational financial model would justify for a population of a few thousand patients. Ultragenyx has built its entire business around exactly this kind of bet, and Fayuvi is the second gene therapy approval the company has received in 2026, following Genglycos for glycogen storage disease Type Ia in August.

The Price and What It Means

The $3.95 million list price will generate significant commentary, and some of it will be justified. It is a number that strains the reimbursement infrastructure of most health systems and raises legitimate questions about who will actually be able to access the therapy. Ultragenyx has established an UltraCare program with dedicated gene therapy guides to help families navigate insurance coverage, and the company has indicated it will work with payers on outcomes-based agreements. Whether those mechanisms will be sufficient to ensure broad access is genuinely uncertain.

But the price also reflects a real economic reality. Developing a gene therapy for a disease affecting a few thousand patients globally requires years of research, multiple clinical trials, specialized manufacturing infrastructure, and regulatory expertise, all deployed for a market that is, by definition, tiny. The $3.95 million figure is not simply a number extracted from a captive patient population. It is, at least in part, a reflection of what it costs to develop treatments for diseases that the market would otherwise ignore entirely. The Priority Review Voucher the FDA awarded alongside the approval, which Ultragenyx can sell to another company for hundreds of millions of dollars, is itself a policy mechanism designed to subsidize exactly this kind of development by providing a financial return that the disease market alone cannot generate.

None of that makes the access question less urgent. It makes it more complicated. The tension between the cost of developing rare disease therapies and the ability of health systems to pay for them is not going to be resolved by any single approval or any single pricing decision. It is a structural problem that requires structural solutions, including outcomes-based contracting, multi-year payment arrangements, and potentially public investment in the development of therapies for the rarest diseases. Fayuvi's approval puts that conversation back on the table in a concrete and immediate way.

What This Signals for the Field

The approval of Fayuvi is the latest in a series of gene therapy approvals for ultra-rare neurological diseases that have arrived in rapid succession. Zanvastro for Alexander disease was approved in September 2026. uniQure submitted a BLA for Huntington's disease gene therapy in the same month. The pattern reflects both the maturation of AAV gene therapy as a platform and the FDA's demonstrated willingness to apply the accelerated approval framework and other regulatory flexibilities to diseases where the unmet need is severe and the patient population is too small to support conventional trial designs.

For Ultragenyx, the Fayuvi approval is a validation of a business model that has always been more about scientific conviction than commercial optimization. The company's CEO Emil Kakkis described the approval as reflecting years of research and unwavering support from families and patient organizations in the face of a devastating, universally fatal disease. That framing is accurate, and it points to something that gets lost in discussions about drug pricing and market dynamics: the people who made this therapy possible include not just scientists and regulators and company executives, but parents who fundraised, advocated, enrolled their children in trials, and refused to accept that nothing could be done.

For those families, the approval of Fayuvi does not erase the years of waiting or the children who did not survive long enough to benefit from it. What it does is change the fundamental nature of what a diagnosis of Sanfilippo syndrome Type A means. It is no longer a sentence with no possible response. That shift, from nothing to something, is what the word "first" actually means in this context. The price tag is a problem to be solved. The therapy itself is a genuine achievement, and it deserves to be recognized as one.